EE504 Buprenorphine –Naloxone Film Yields Cost Savings in Administration Time Compared With Sublingual Tablets in Sweden
This analysis explores potential savings with BN film over sublingual tablets over 2 years, from the perspective of the Swedish healthcare system. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: P. Macnair, A.C. Johansson, C. Gadeon, M. Sandell, H. Barham, M. Kabra, S. Meyner, K. Olsson Source Type: research
Mobile service delivery in response to the opioid epidemic in Philadelphia
CONCLUSIONS: MOCUs provide life-saving services and engage marginalized individuals with OUD. These findings highlight the challenges and complexities of caring for PWID and demonstrate a need to strengthen collaborations between MOCU providers and the treatment system. Policymakers should consider programmatic funding for permanent mobile OUD care services.PMID:38031174 | PMC:PMC10687974 | DOI:10.1186/s13722-023-00427-5 (Source: Addiction Science and Clinical Practice)
Source: Addiction Science and Clinical Practice - November 30, 2023 Category: Addiction Authors: Rebecca E Stewart Hanna P Christian Nicholas C Cardamone Catherine Abrams Caroline Drob David S Mandell David Metzger Margaret Lowenstein Source Type: research
Mobile service delivery in response to the opioid epidemic in Philadelphia
CONCLUSIONS: MOCUs provide life-saving services and engage marginalized individuals with OUD. These findings highlight the challenges and complexities of caring for PWID and demonstrate a need to strengthen collaborations between MOCU providers and the treatment system. Policymakers should consider programmatic funding for permanent mobile OUD care services.PMID:38031174 | PMC:PMC10687974 | DOI:10.1186/s13722-023-00427-5 (Source: Addiction Science and Clinical Practice)
Source: Addiction Science and Clinical Practice - November 30, 2023 Category: Addiction Authors: Rebecca E Stewart Hanna P Christian Nicholas C Cardamone Catherine Abrams Caroline Drob David S Mandell David Metzger Margaret Lowenstein Source Type: research
Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone
Clin Pharmacol Ther. 2023 Nov 27. doi: 10.1002/cpt.3112. Online ahead of print.ABSTRACTMethadone and buprenorphine/naloxone are opioid agonist therapies for opioid use disorder treatment. Genetic factors contribute to individual differences in opioid response; however, little is known regarding genetic associations with clinical outcomes in people receiving opioid agonist therapies. Participants diagnosed with opioid use disorder, principally consisting of prescription opioids (licit or illicit), were randomized to methadone or buprenorphine/naloxone for 24 weeks of daily treatment (NCT03033732). Urine was collected at 12 ...
Source: Clinical Pharmacology and Therapeutics - November 27, 2023 Category: Drugs & Pharmacology Authors: Intishar Kazi Meghan J Chenoweth Didier Jutras-Aswad Keith Ahamad M Eugenia Socias Bernard Le Foll Rachel F Tyndale Source Type: research
Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone
Clin Pharmacol Ther. 2023 Nov 27. doi: 10.1002/cpt.3112. Online ahead of print.ABSTRACTMethadone and buprenorphine/naloxone are opioid agonist therapies for opioid use disorder treatment. Genetic factors contribute to individual differences in opioid response; however, little is known regarding genetic associations with clinical outcomes in people receiving opioid agonist therapies. Participants diagnosed with opioid use disorder, principally consisting of prescription opioids (licit or illicit), were randomized to methadone or buprenorphine/naloxone for 24 weeks of daily treatment (NCT03033732). Urine was collected at 12 ...
Source: Clinical Pharmacology and Therapeutics - November 27, 2023 Category: Drugs & Pharmacology Authors: Intishar Kazi Meghan J Chenoweth Didier Jutras-Aswad Keith Ahamad M Eugenia Socias Bernard Le Foll Rachel F Tyndale Source Type: research
Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone
Clin Pharmacol Ther. 2023 Nov 27. doi: 10.1002/cpt.3112. Online ahead of print.ABSTRACTMethadone and buprenorphine/naloxone are opioid agonist therapies for opioid use disorder treatment. Genetic factors contribute to individual differences in opioid response; however, little is known regarding genetic associations with clinical outcomes in people receiving opioid agonist therapies. Participants diagnosed with opioid use disorder, principally consisting of prescription opioids (licit or illicit), were randomized to methadone or buprenorphine/naloxone for 24 weeks of daily treatment (NCT03033732). Urine was collected at 12 ...
Source: Clinical Pharmacology and Therapeutics - November 27, 2023 Category: Drugs & Pharmacology Authors: Intishar Kazi Meghan J Chenoweth Didier Jutras-Aswad Keith Ahamad M Eugenia Socias Bernard Le Foll Rachel F Tyndale Source Type: research
Nonprescription use of buprenorphine tablets among patients at a tertiary care addictive disorder treatment center in India: Observa-tions and implications
CONCLUSION: Nonprescription use of tablets buprenorphine and -buprenorphine-naloxone is a clinical concern and also an important public health issue. Geographical and systemic expansions of the availability of buprenorphine may reduce the "demand" for nonprescribed buprenorphine, while the opportunities for diversion from treatment centers can be minimized through more careful clinical prescriptions and monitoring practices.PMID:37968974 | DOI:10.5055/jom.0814 (Source: Journal of Opioid Management)
Source: Journal of Opioid Management - November 16, 2023 Category: Addiction Authors: Yatan Pal Singh Balhara Priyanka Saha Merlin Mathew Mukul Kumar Arpit Parmar Rakesh Lal Siddharth Sarkar Source Type: research
